ProCE Banner Activity

Phase III EMPOWER-Lung 1 and 3: Updated Long-term Subgroup Analysis of Cemiplimab in Newly Diagnosed Advanced NSCLC With Liver Metastases

Conference Coverage

This exploratory subgroup analysis with a median follow-up of more than 28 months demonstrates continued clinical benefit of first-line cemiplimab-based therapy compared with chemotherapy in patients with advanced NSCLC and baseline liver metastases.

Released: September 19, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc. and Regeneron Pharmaceuticals, Inc


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc